A phase I trial of EB 1020 in volunteers.

Trial Profile

A phase I trial of EB 1020 in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2012

At a glance

  • Drugs Centanafadine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2012 Status changed from recruiting to completed, as reported in a Neurovance media release.
    • 22 Mar 2012 Results are expected by the end of 2012, according to a Euthymics media release.
    • 22 Mar 2012 Status changed from not yet recruiting to recruiting, according to a Euthymics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top